Match tier
Listed
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-08-20
Biography and Research Information
OverviewAI-generated summary
Sydnye L. Shuttleworth's research investigates therapeutic targets and molecular mechanisms in cancer and infectious diseases. Her work includes studying NEK2 as a therapeutic target in lymphoma and exploring T cell exhaustion in solid tumors, for which she received a $40,026 NIH/National Cancer Institute grant as PI. Shuttleworth also examines the role of specific compounds, such as 4-4-(Anilinomethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-ylbenzoic acid derivatives, as antibacterial agents against gram-positive bacteria.
Her research also extends to understanding metabolic plasticity in T cells within the context of glioblastoma and proteomic analysis of T cell exhaustion, including the DNA damage response. Shuttleworth collaborates with multiple researchers at the University of Arkansas for Medical Sciences, including Vijay Patel, Ying-Zhi Xu, Mason McCrury, and Kennith Swafford, with whom she shares 46 publications.
Metrics
- h-index: 2
- Publications: 72
- Citations: 50
Selected Publications
-
Proteostasis sustains T cell differentiation potential and tumor-infiltrating lymphocyte function (2026)
-
743 Proteostasis sustains T cell differentiation potential and tumor-infiltrating lymphocyte function (2025)
-
685 EZH2 inhibition impairs CD8+ CAR-T cell persistence (2025)
-
691 ATF6 activation promotes ICB response in melanoma (2025)
-
762 CD28 costimulation induces PCK2 to support T cell effector function in metabolically hostile environments (2025)
-
236 Manipulating the DNA damage response to combat T cell exhaustion and improve immunotherapy response (2025)
-
277 Proteome turnover dynamics analysis uncovers E3 ligases that enhance T-cell persistence during exhaustion (2025)
-
392 Donor-intrinsic proteomic programs shape CAR-T cell persistence across a longitudinal killing assay (2025)
-
Comprehensive Analysis of Proteome Turnover Dynamics During T Cell Exhaustion (2025)
-
854 Protein homeostasis enables T cell differentiation potential and sustains TIL function in cancer (2024)
-
319 Comprehensive analysis of proteome turnover dynamics during T cell exhaustion (2024)
-
929 Proteomic analysis reveals differential modulation of the DNA damage response in exhausted T cells (2024)
-
932 Defining the role for PCK2 in T-cell metabolic plasticity (2024)
Federal Grants 1 $40,602 total
NIH
Contact PI
Aug 2025 - Jul 2029
Leveraging the E3 Ligase RNF166 to Prevent T Cell Exhaustion in Solid Tumors
Collaboration Network
Top Collaborators
Analiz Rodriguez
University of Arkansas for Medical Sciences
2 shared publications
In database
- Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- 1211 Defining the role of PCK2 in T cell metabolic plasticity in Glioblastoma
Latambria Hampton
University of Arkansas for Medical Sciences
2 shared publications
In database
- 1020 Proteomic analysis of T cell exhaustion unveils differential modulation of the DNA damage response
- 1211 Defining the role of PCK2 in T cell metabolic plasticity in Glioblastoma
Lora J. Rogers
University of Arkansas for Medical Sciences
2 shared publications
In database
- 1020 Proteomic analysis of T cell exhaustion unveils differential modulation of the DNA damage response
- 1211 Defining the role of PCK2 in T cell metabolic plasticity in Glioblastoma
Daniel Fil
University of Arkansas for Medical Sciences
2 shared publications
In database
- 1020 Proteomic analysis of T cell exhaustion unveils differential modulation of the DNA damage response
- 1211 Defining the role of PCK2 in T cell metabolic plasticity in Glioblastoma
Brian Koss
University of Arkansas for Medical Sciences
2 shared publications
In database
- 1020 Proteomic analysis of T cell exhaustion unveils differential modulation of the DNA damage response
- 1211 Defining the role of PCK2 in T cell metabolic plasticity in Glioblastoma
Raj KC. Hansa
Arkansas State University
1 shared publication
In database
- 4-4-(Anilinomethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-ylbenzoic acid derivatives as potent anti-gram-positive bacterial agents
Md Mahbub Kabir Khan
Arkansas State University (US)
1 shared publication
- 4-4-(Anilinomethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-ylbenzoic acid derivatives as potent anti-gram-positive bacterial agents
Melissa M. Frangie
Arkansas State University
1 shared publication
In database
- 4-4-(Anilinomethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-ylbenzoic acid derivatives as potent anti-gram-positive bacterial agents
David F. Gilmore
Arkansas State University
1 shared publication
In database
- 4-4-(Anilinomethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-ylbenzoic acid derivatives as potent anti-gram-positive bacterial agents
Robert S. Shelton
University of Arkansas for Medical Sciences
1 shared publication
In database
- 4-4-(Anilinomethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-ylbenzoic acid derivatives as potent anti-gram-positive bacterial agents
Alena V. Savenka
University of Arkansas for Medical Sciences
1 shared publication
In database
- 4-4-(Anilinomethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-ylbenzoic acid derivatives as potent anti-gram-positive bacterial agents
Alexei G. Basnakian
University of Arkansas for Medical Sciences
1 shared publication
In database
- 4-4-(Anilinomethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-ylbenzoic acid derivatives as potent anti-gram-positive bacterial agents
Mark S. Smeltzer
University of Arkansas for Medical Sciences
1 shared publication
In database
- 4-4-(Anilinomethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-ylbenzoic acid derivatives as potent anti-gram-positive bacterial agents
Mohammad A. Alam
Arkansas State University
1 shared publication
In database
- 4-4-(Anilinomethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-ylbenzoic acid derivatives as potent anti-gram-positive bacterial agents
Mason McCrury
University of Arkansas for Medical Sciences
1 shared publication
In database
- Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
Similar Researchers
Based on overlapping research topics
Cade Richesin
University of Arkansas at Fayetteville
Lymphoma Diagnosis and Treatment
Cancer Treatment and Pharmacology
Immune Response and Inflammation
Camila Simões
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Immune Response and Inflammation
Disease Mechanisms Research
Jacob L Edmondson
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Immune Response and Inflammation
Disease Mechanisms Research
Gaven K. Smart
University of Arkansas at Fayetteville
Cancer Treatment and Pharmacology
Immune Response and Inflammation
Disease Mechanisms Research
Claire Doshier
University of Arkansas for Medical Sciences
Lymphoma Diagnosis and Treatment
Immune Response and Inflammation
Disease Mechanisms Research
Sean Plummer
University of Arkansas at Fayetteville
Lymphoma Diagnosis and Treatment
Cancer Treatment and Pharmacology
Immune Response and Inflammation